NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ranok Therapeutics

Ranok Therapeutics

Private
HangzhouHealthcare & Life Scienceshttps://ranoktherapeutics.com/

Last Round

Series B

Aug 18, 2021

Total Funding Raised

$40M

Company Overview

Ranok Therapeutics is a drug discovery company that develops an innovative targeted protein degradation technology for the discovery and development of novel therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

targeted protein degradationTPDCHAMP platformChaperone-mediated Protein Degradationprotein degraderundruggable targetsoncology therapeuticsKRAS G12D inhibitorsmall molecule drugsclinical-stage biopharmadrug discovery platformsolid tumorsBRD4 degrader

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ranok Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Ranok Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ranok Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 18, 2021
SeedMar 27, 2020

Key People

Founding team and executive leadership

Kevin Foley

Co-founder & Chief Scientific Officer

Founding Team

Weiwen Ying

Chief Executive Officer

Executive Team

Nathan CHANG

Chief Financial Officer

Executive Team

Ranok Therapeutics Investors

Notable investors and investment history

Ranok Therapeutics investors
InvestorRounds
Shanghai Healthcare CapitalSeries B
Wu CapitalSeries B
Lapam CapitalSeries B

Ranok Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ranok Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ranok Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range11
Year Founded2018
Last FundingAug 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.